摘要
目的研究西妥昔单抗联合紫杉醇对人鼻咽癌CNE-1细胞活力的影响及其可能分子机制。方法培养人鼻咽癌CNE-1细胞株,分为空白对照组、西妥昔单抗组、紫杉醇组、联合用药组,通过噻唑蓝(MTT)法检测细胞活力、划痕试验检测细胞迁移能力、Western-blot法检测基质金属蛋白酶2(MMP-2)、表皮生长因子受体(EGFR)的mRNA和蛋白水平。结果 1联合用药组的MTT值(36±7)和迁移能力相对值(21±6),低于西妥昔单组的MTT值(62±10)、迁移能力相对值(55±10)和紫杉醇组的MTT值(59±11)、迁移能力相对值(57±10),差异有统计学意义(P<0.05)。2联合用药组EFGR、MMP-2的mRNA含量分别为(50±14)、(45±11),低于西妥昔单组的(67±18)、(69±16)和紫杉醇组的(60±17)、(64±19),差异均有统计学意义(P<0.05);联合用药组的EFGR、MMP-2蛋白含量分别为(43±13)、(36±8),低于西妥昔单组的(69±15)、(64±10)和紫杉醇组(56±14)、(63±9),差异均有统计学意义(均P<0.05)。结论西妥昔单抗联合紫杉醇能够抑制人鼻咽癌CNE-1细胞的增殖和迁移能力,这一作用可能是通过抑制EFGR、MMP-2的表达来实现的。
Objective To study the effect of cetuximab combined with paclitaxel on proliferation and migration of nasopharyngeal carcinoma cell line CNE-I and its possible molecular mechanism. Methods Nasopharyngeal carcinoma cell line CNE-1 were cultured and divided into blank contrast group, cetuximab group, paclitaxel group and combination group. Then ceil vitality was detected by MTT, migration was detec- ted by wound-healing assay and level of matrix metalloproteinase-2 ( MMP-2), epithelial growth factor recep- tor (EGFR) was detected by real-time PCR and Western-blot. Results (±)MTT value(36 ± 7 ) and migra- tion ability(21 ±6) of the combination group were lower than MTY value(62 ± 10) and migration ability(55 ± 10) of the cetuximab group, MTY value(59 ± 11 ) and migration ability(57 ± 10 ) of the paclitaxel group (P 〈0.05). (±)EGFR, MMP-2 mRNA levels (50 ± 14), (45 ± 11 ) of the combination group were lower than (67 ± 18), (69 ± 16) of the cetuximab group, (60 ± 17), (64 ± 19) of the paclitaxel group(P 〈 0.05 ) ;EGFR, MMP-2 protein levels (43 ± 13 ), (36 ± 8 ) of the combination group were lower than (69 ± 15 ), (64 ± 10 ) of the cetuximab group and ( 56 ± 14 ), ( 63 ± 9 ) of the paclitaxel group ( P 〈 0.05 ). Conclusion Ceumimab combined With paclitaxel can reduce the migration and proliferation ability of carci- noma cell line CNE-1, and inhibition on MMP-2, EGFR might be the molecular mechanisms.
出处
《医学综述》
2015年第20期3822-3825,共4页
Medical Recapitulate
关键词
鼻咽癌
西妥昔单抗
紫杉醇
增殖
迁移
Nasopharyngeal carcinoma
Cetuximab
Paclitaxel
Proliferation
Migration